Veracyte Inc (NASDAQ:VCYT) insider Giulia C. Kennedy sold 15,327 shares of Veracyte stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $26.47, for a total value of $405,705.69. Following the completion of the transaction, the insider now owns 47,157 shares of the company’s stock, valued at $1,248,245.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of VCYT traded up $2.08 during midday trading on Wednesday, reaching $28.34. The stock had a trading volume of 996,729 shares, compared to its average volume of 643,694. Veracyte Inc has a 1-year low of $10.73 and a 1-year high of $31.18. The company’s fifty day simple moving average is $24.90 and its two-hundred day simple moving average is $25.82. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -45.73 and a beta of 1.14.
Veracyte (NASDAQ:VCYT) last posted its earnings results on Tuesday, October 22nd. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.05. The firm had revenue of $30.97 million for the quarter, compared to analyst estimates of $30.41 million. Veracyte had a negative return on equity of 5.33% and a negative net margin of 7.08%. Research analysts expect that Veracyte Inc will post -0.19 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of VCYT. Boston Advisors LLC increased its stake in Veracyte by 114.1% in the third quarter. Boston Advisors LLC now owns 54,066 shares of the biotechnology company’s stock valued at $1,298,000 after purchasing an additional 28,812 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new position in Veracyte during the 3rd quarter worth approximately $2,018,000. California Public Employees Retirement System grew its stake in Veracyte by 15.5% during the 3rd quarter. California Public Employees Retirement System now owns 189,319 shares of the biotechnology company’s stock worth $4,544,000 after buying an additional 25,350 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new position in Veracyte during the second quarter worth approximately $229,000. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Veracyte by 144.4% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,764,236 shares of the biotechnology company’s stock valued at $66,342,000 after buying an additional 1,633,287 shares during the last quarter.
Veracyte Company Profile
Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
Featured Story: What is the S&P/ASX 200 Index?
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.